公开(公告)号：US08017610B2

公开(公告)日：2011-09-13

申请号：US12843348

申请日：2010-07-26

申请人： Akihiro Furukawa ,  Takehiro Fukuzaki ,  Yukari Onishi ,  Hideki Kobayashi ,  Takeshi Honda ,  Yumi Matsui ,  Masahiro Konishi ,  Kenjiro Ueda ,  Tetsuyoshi Matsufuji

发明人： Akihiro Furukawa ,  Takehiro Fukuzaki ,  Yukari Onishi ,  Hideki Kobayashi ,  Takeshi Honda ,  Yumi Matsui ,  Masahiro Konishi ,  Kenjiro Ueda ,  Tetsuyoshi Matsufuji

IPC分类号： A61K31/501 ,  A61K31/497 ,  A61K31/443 ,  A61K31/421 ,  C07D403/14 ,  C07D413/14 ,  C07D265/08

CPC分类号： C07D413/14 ,  C07D207/333 ,  C07D207/335 ,  C07D207/337 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14

摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].

摘要翻译： 本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或 硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基 独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成 取代 具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同） 或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环 选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

公开(公告)号：US20110003787A1

公开(公告)日：2011-01-06

申请号：US12843348

申请日：2010-07-26

申请人： Akihiro Furukawa ,  Takehiro Fukuzaki ,  Yukari Onishi ,  Hideki Kobayashi ,  Takeshi Honda ,  Yumi Matsui ,  Masahiro Konishi ,  Kenjiro Ueda ,  Tetsuyoshi Matsufuji

发明人： Akihiro Furukawa ,  Takehiro Fukuzaki ,  Yukari Onishi ,  Hideki Kobayashi ,  Takeshi Honda ,  Yumi Matsui ,  Masahiro Konishi ,  Kenjiro Ueda ,  Tetsuyoshi Matsufuji

IPC分类号： A61K31/427 ,  C07D417/04 ,  C07D413/14 ,  C07D413/12 ,  A61P3/10 ,  A61K31/501 ,  A61K31/4439 ,  A61K31/428 ,  C07D403/04 ,  A61K31/497 ,  C07D207/34 ,  A61K31/40 ,  C07D413/04 ,  A61K31/422 ,  A61K31/5355 ,  C07D417/14 ,  A61K31/5377

CPC分类号： C07D413/14 ,  C07D207/333 ,  C07D207/335 ,  C07D207/337 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14

摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].

摘要翻译： 本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或 硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基 独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成 取代 具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同） 或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环 选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

公开(公告)号：US08415359B2

公开(公告)日：2013-04-09

申请号：US13198819

申请日：2011-08-05

申请人： Akihiro Furukawa ,  Takehiro Fukuzaki ,  Yukari Onishi ,  Hideki Kobayashi ,  Takeshi Honda ,  Yumi Matsui ,  Masahiro Konishi ,  Kenjiro Ueda ,  Tetsuyoshi Matsufuji

发明人： Akihiro Furukawa ,  Takehiro Fukuzaki ,  Yukari Onishi ,  Hideki Kobayashi ,  Takeshi Honda ,  Yumi Matsui ,  Masahiro Konishi ,  Kenjiro Ueda ,  Tetsuyoshi Matsufuji

IPC分类号： A61K31/497 ,  A61K31/4439 ,  A61K31/443 ,  A61K31/428 ,  A61K31/427 ,  A61K31/421 ,  A61K31/4155 ,  A61K31/4025 ,  A61K31/40 ,  C07D401/14 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D277/62 ,  C07D277/20 ,  C07D263/08 ,  C07D263/30 ,  C07D403/04 ,  C07D403/14 ,  C07D207/323

CPC分类号： C07D413/14 ,  C07D207/333 ,  C07D207/335 ,  C07D207/337 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14

摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].

摘要翻译： 本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或 硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基 独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成 取代 具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同） 或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环 选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

公开(公告)号：US20090036492A1

公开(公告)日：2009-02-05

申请号：US11990289

申请日：2006-08-08

申请人： Akihiro Furukawa ,  Jun Ohsumi ,  Tsuyoshi Arita ,  Takehiro Fukuzaki ,  Kazushi Araki ,  Makoto Mori ,  Takayuki Momose ,  Takeshi Honda ,  Masanori Kuroha ,  Ryo Okuyama ,  Susumu Satoh

发明人： Akihiro Furukawa ,  Jun Ohsumi ,  Tsuyoshi Arita ,  Takehiro Fukuzaki ,  Kazushi Araki ,  Makoto Mori ,  Takayuki Momose ,  Takeshi Honda ,  Masanori Kuroha ,  Ryo Okuyama ,  Susumu Satoh

IPC分类号： A61K31/443 ,  C07D307/91 ,  C07D405/12 ,  A61K31/343

CPC分类号： C07D307/91 ,  C07D405/12 ,  C07D407/12

摘要： The present invention relates to a novel cercosporamide derivative, a pharmacologically acceptable salt thereof or an ester thereof which has an excellent hypoglycemic effect and is useful as a therapeutic and/or prophylactic agent for diabetes.A cercosporamide derivative having the general formula (I): [wherein X represents an oxygen atom or the like, R1 represents a hydrogen atom or a C1-C6 alkyl group, R2 represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 halogenated alkyl group, R3 represents a hydrogen atom or a C1-C6 alkyl group, R4 represents a C6-C10 aryl group which may be substituted with one to five group(s) independently selected from Substituent Group a, or the like, n represents 1, 2 or 3, and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, a C2-C6 alkenyloxy group, a C2-C6 alkynyloxy group and the like], a pharmacologically acceptable salt thereof or an ester thereof.

摘要翻译： 本发明涉及一种具有优异的降血糖作用，可用作糖尿病治疗和/或预防剂的新颖的孢子虫素衍生物，其药理学上可接受的盐或其酯。 具有通式（I）的孢孢酰胺衍生物：[其中X表示氧原子等，R 1表示氢原子或C 1 -C 6烷基，R 2表示氢原子，C 1 -C 6烷基或C 1 -C 6卤代烷基，R 3表示氢原子或C 1 -C 6烷基，R 4表示可以被一至五个独立地选自取代基组a的基团取代的C 6 -C 10芳基等， n表示1,2或3，取代基组a表示卤素原子，C1-C6烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6 烷氧基，C1-C6卤代烷氧基，C2-C6链烯氧基，C2-C6炔氧基等]，其药理学上可接受的盐或其酯。

公开(公告)号：US20090137499A1

公开(公告)日：2009-05-28

申请号：US12280510

申请日：2007-08-03

申请人： Takeshi Honda ,  Minoru Oguchi ,  Masao Yoshida ,  Ryo Okuyama ,  Tsuneaki Ogata ,  Manabu Abe ,  Kenjiro Ueda ,  Jun Ohsumi ,  Masanori Izumi

发明人： Takeshi Honda ,  Minoru Oguchi ,  Masao Yoshida ,  Ryo Okuyama ,  Tsuneaki Ogata ,  Manabu Abe ,  Kenjiro Ueda ,  Jun Ohsumi ,  Masanori Izumi

IPC分类号： A61K31/706 ,  C07G3/00 ,  A61K31/7004 ,  C07H17/02

CPC分类号： C07H15/203 ,  A61K9/2018 ,  C07H17/02

摘要： The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I): wherein R1 represents a hydrogen atom, an amino group, a hydroxy C1-C6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, etc.; R4 represents a hydrogen atom, a C2-C7 acyl group, etc.; R5, R6, R7, and R8 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, provided that R5, R6, R7 and R8 are not hydrogen atoms at the same time; n is 0 to 4; and X is CH or N.

摘要翻译： 本发明涉及对人SGLT1和/或SGLT2活性具有优异抑制作用的苄基苯基吡喃葡萄糖苷衍生物。 提供由以下通式（I）表示的化合物或其药理学上可接受的盐：其中R1表示氢原子，氨基，羟基C1-C6烷基等; R2表示氢原子等; R3表示C1-C6烷基，羟基C1-C6烷基等; R4表示氢原子，C2-C7酰基等; R5，R6，R7和R8相同或不同，各自表示氢原子或C1-C6烷基，条件是R5，R6，R7和R8不同时为氢原子; n为0〜4; X为CH或N.

公开(公告)号：US08754112B2

公开(公告)日：2014-06-17

申请号：US13388218

申请日：2010-08-04

申请人： Shigeo Yamanoi ,  Hidenori Namiki ,  Takahiro Katagiri ,  Mayuko Akiu ,  Katsuji Kagechika ,  Takeshi Honda ,  Koji Matsumoto ,  Ryutaro Nakashima

发明人： Shigeo Yamanoi ,  Hidenori Namiki ,  Takahiro Katagiri ,  Mayuko Akiu ,  Katsuji Kagechika ,  Takeshi Honda ,  Koji Matsumoto ,  Ryutaro Nakashima

IPC分类号： A61K31/4245 ,  C07D271/06

CPC分类号： C07D271/06 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/12 ,  C07D413/14

摘要： Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

摘要翻译： 提供具有优异的降血糖作用的化合物或其药学上可接受的盐，以及对1型糖尿病，2型糖尿病等具有优异的治疗效果和/或预防效果的药物组合物，其引起增加 血糖水平由于糖代谢异常。 公开了由通式（I）表示的化合物或其药学上可接受的盐。

公开(公告)号：US08737119B2

公开(公告)日：2014-05-27

申请号：US13433895

申请日：2012-03-29

申请人： Takeshi Honda ,  Noboru Sakimura ,  Tadahiko Sugibayashi ,  Hideaki Numata ,  Norikazu Ohshima

发明人： Takeshi Honda ,  Noboru Sakimura ,  Tadahiko Sugibayashi ,  Hideaki Numata ,  Norikazu Ohshima

IPC分类号： G11C11/16

CPC分类号： H01L27/228 ,  B82Y10/00 ,  G11C11/161 ,  G11C11/1655 ,  G11C11/1657 ,  G11C11/1659 ,  G11C11/1675 ,  H01L43/08

摘要： A magnetic memory cell 1 is provided with a magnetic recording layer 10 which is a ferromagnetic layer and a pinned layer 30 connected with the magnetic recording layer 10 through a non-magnetic layer 20. The magnetic recording layer 10 has a magnetization inversion region 13, a first magnetization fixed region 11 and a second magnetization fixed region 12. The magnetization inversion region 13 has a magnetization whose orientation is invertible and overlaps the pinned layer 30. The first magnetization fixed region 11 is connected with a first boundary B1 in the magnetization inversion region 13 and a magnetization orientation is fixed on a first direction. The second magnetization fixed region 12 is connected with a second boundary B2 in magnetization inversion region 13 and a magnetization orientation is fixed on a second direction. The first direction and the second direction are opposite to each other.

摘要翻译： 磁存储单元1设置有磁记录层10，磁记录层10是铁磁层，和通过非磁性层20与磁记录层10连接的钉扎层30.磁记录层10具有磁化反转区域13， 第一磁化固定区域11和第二磁化固定区域12.磁化反转区域13具有其取向可反转并与被钉扎层30重叠的磁化。第一磁化固定区域11与磁化反转中的第一边界B1连接 区域13和磁化取向在第一方向固定。 第二磁化固定区域12与磁化反转区域13中的第二边界B2连接，并且磁化取向固定在第二方向上。 第一方向和第二方向彼此相反。

公开(公告)号：US20140118809A1

公开(公告)日：2014-05-01

申请号：US14128512

申请日：2012-06-08

申请人： Takeshi Honda ,  Kenji Tagami ,  Nobuaki Takanashi

发明人： Takeshi Honda ,  Kenji Tagami ,  Nobuaki Takanashi

IPC分类号： G02B26/10

CPC分类号： G02B26/10 ,  G02B26/105

摘要： Provided is an optical scanning device capable of solving the problem of low driving efficiency. A pair of coupling parts 12 join both ends of movable mirror part 11 having a reflective plane that reflects light to respective supporting parts 13. Each coupling part 12 has magnet part 21 having a permanent magnet, first spring part 22 that couples magnet part 21 to supporting part 13 in an oscillatable manner, and a second spring part that couples movable mirror part 11 to magnet part 21 in an oscillatable manner. Driver 14 generates magnetic fields acting on magnet part 21 to oscillate magnetic part 21 and thereby oscillate movable mirror part 11.

摘要翻译： 提供了能够解决驾驶效率低的问题的光学扫描装置。 一对联接部件12将可反射镜部分11的两端连接成具有将光反射到相应的支撑部分13的反射平面。每个连接部分12具有具有永磁体的磁体部分21，将磁体部分21耦合到 支撑部件13以可振动的方式，以及第二弹簧部件，其以可振荡的方式将可动镜部件11耦合到磁体部件21。 驱动器14产生作用在磁体部分21上的磁场，以振荡磁性部分21，从而振动可动镜部分11。

公开(公告)号：US08693238B2

公开(公告)日：2014-04-08

申请号：US12376925

申请日：2007-07-13

申请人： Noboru Sakimura ,  Takeshi Honda ,  Tadahiko Sugibayashi

发明人： Noboru Sakimura ,  Takeshi Honda ,  Tadahiko Sugibayashi

IPC分类号： G11C11/00 ,  G11C8/00

CPC分类号： G11C8/08 ,  G11C11/1659 ,  G11C11/1675

摘要： An MRAM of a spin transfer type is provided with a memory cell 10 and a word driver 30. The memory cell 10 has a magnetic resistance element 1 and a selection transistor TR having one of source/drain electrodes which is connected with one end of the magnetic resistance element 1. The word driver 30 drives a word line WL connected with a gate electrode of the selection transistor TR. The word driver 30 changes a drive voltage of the word line WL according to the write data DW to be written in the magnetic resistance element 1.

摘要翻译： 自旋转移型的MRAM具有存储单元10和字驱动器30.存储单元10具有磁阻元件1和选择晶体管TR，其具有与源极/漏极之一连接的源极/漏极之一 字驱动器30驱动与选择晶体管TR的栅电极连接的字线WL。 字驱动器30根据要写入磁阻元件1的写数据DW改变字线WL的驱动电压。

公开(公告)号：US08281221B2

公开(公告)日：2012-10-02

申请号：US12083373

申请日：2006-10-17

申请人： Noboru Sakimura ,  Takeshi Honda ,  Tadahiko Sugibayashi

发明人： Noboru Sakimura ,  Takeshi Honda ,  Tadahiko Sugibayashi

IPC分类号： G06F11/00

CPC分类号： G11C11/16 ,  G06F11/1044 ,  G06F11/1076 ,  G11C11/1653 ,  G11C11/1673 ,  G11C11/1675 ,  G11C2029/0411 ,  G11C2211/5641

摘要： An operation method of a MRAM of the present invention stores in memory arrays, error correction codes, each of which comprises of symbols, each of which comprises bits, and to which an error correction is possible in units of symbols. In the operation method, the symbols are read by using the reference cells different from each other. Moreover, when a correctable error is detected in a read data of the error correction code from data cells corresponding to an input address, (A) a data in the data cell corresponding to an error bit is corrected, for a first error symbol as an error pattern of one bit, and (B) a data in the reference cell that is used to read a second error symbol is corrected for a second error symbol as en error pattern of the bits.

摘要翻译： 本发明的MRAM的操作方法存储在存储器阵列中，每个都包括符号，每个符号包括位，并且可以以符号为单位进行纠错。 在操作方法中，通过使用彼此不同的参考单元来读取符号。 此外，当在对应于输入地址的数据单元的错误校正码的读取数据中检测到可校正错误时，（A）对与错误位对应的数据单元中的数据进行校正，对于第一错误符号，作为 一个比特的错误模式和（B）用于读取第二错误符号的参考小区中的数据被校正为第二个错误符号作为比特的错误模式。